(Source: PRNewswire)SAN DIEGO, Aug. 6 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR), The Leading Provider of Real Estate to the Life Science Industry(R), announced today that its board of directors and corporate officers will ring The Closing Bell(R) at the New York Stock Exchange on Thursday, August 6, 2009 at 4:00 p.m. Eastern Time to commemorate the fifth anniversary of the company's initial public offering. The ceremony will take place at the New York Stock Exchange, 11 Wall Street in New York City. BioMed's founders, Alan D. Gold, Chairman and Chief Executive Officer, and Gary A. Kreitzer, Executive Vice President, General Counsel and Director, will preside over the ringing of The Closing Bell(R).

"This is a great day for our team," said Mr. Gold. "Through their hard, smart work, our industry-leading team of professionals, now over 125 strong, has consistently produced results well beyond the initial expectations we had on that first day of trading in 2004, when we owned interests in just five properties, representing less than 400,000 square feet and generating less than $12 million in annualized base rents. Today, five years later, we have assembled the industry-leading portfolio of life science real estate, including 69 properties representing 10.5 million square feet and roughly $280 million in annualized base rents. While we are pleased with our progress to date, we are even more excited about the future for BioMed and the opportunity we see to create value for our shareholders, building on the strong foundation that we have established."

Mr. Gold further noted, "We are very encouraged by the significant volume of partnership transactions and capital raising we have observed in the life science industry over the last several months, particularly within our tenant portfolio. And while we remain very cautious with respect to the current leasing environment, the recent capital raising successes from our tenants serve as an indication that the primary mechanisms for funding the life science industry appear to be functioning effectively. In particular we note the continuing critical linkage between scientific advancements, capital raising and the leasing of space."

Mr. Gold continued, "It is noteworthy that these capital raising events extend across BioMed's tenant base. While research institutions, A-rated public companies and larger, established public companies comprise the vast majority - roughly 75% - of our tenant base, we are pleased to see healthy capital raising activity from our mid-stage and early-stage tenants as well."

One-half of BioMed's top ten tenants are research institutions or A-rated public companies, including Beth Israel Deaconess Medical Center, Children's Hospital Boston, Genzyme Corporation, Centocor, Inc. (a Johnson & Johnson subsidiary) and Schering Corporation. Each of BioMed's other top ten tenants publicly announced significant capital raising transactions in recent months:

-- On August 3, 2009, Human Genome Sciences, Inc., the company's

largest tenant, raised approximately $357 million in net proceeds from

its common stock offering.

-- On July 30, 2009, Vertex Pharmaceuticals Incorporated, the

company's second largest tenant, announced that it will receive

$105 million, in addition to potential milestone payments, from the sale

of commercialization rights of telaprevir in Japan and other countries

in the Far East to Mitsubishi Tanabe Pharma Corporation, after

announcing its intention to sell certain future European milestone

payments for telaprevir aggregating $250 million earlier in July and

raising approximately $314 million in net proceeds from a common stock

offering in February 2009.